Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies

Daiichi Sankyo announced on May 15 that it will expand its joint research with Canadian biotech Zymeworks in the field of oncology. In addition to a cross-licensing agreement related to bispecific antibodies sealed in 2016, Daiichi Sankyo will acquire the...read more